

## Development of Assisted Reproductive Technology Using Ovarian Cells Derived from iPS Cells(Dioseve Inc.)



Dioseve

City	Year of Establishment	Founder
Koto-ku, Tokyo	2021	Kazuma Kishida

Partner VC	Latest round of Fundraising	Valuation
Archtype Ventures	Series A	-

Contact Information : k-kishida@dioseve.com

Website : <https://dioseve.com/en>

○ Business Plan

1. Oocyte Culture Reagent Business Manufacture and sale of iPS cell-derived ovarian-like cells as an in vitro oocyte culture solution
- 2 .Infertility Treatment Service Business  
Provision of infertility treatment services using oocytes created from the woman's own cells

○ Research Outline

This project involves introducing genes into established allogeneic iPS cells to generate ovarian cells, thereby providing an in vitro egg culture product as a new treatment option for reproductive medicine. This approach significantly improves the success rate of in vitro fertilization while simultaneously reducing the physical and psychological burden on women.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	STS 2025-2026FY	-	United Kingdom

○International collaborative technology demonstration

Through collaboration with the University of Manchester (UoM), we will receive research-grade human oocytes from the UK.